Related references
Note: Only part of the references are listed.Sorafenib Prevents Escape from Host Immunity in Liver Cirrhosis Patients with Advanced Hepatocellular Carcinoma
Hidenari Nagai et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2012)
Sorafenib sensitizes hepatocellular carcinoma cells to physiological apoptotic stimuli
Joan Fernando et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2012)
Sorafenib Overcomes TRAIL Resistance of Hepatocellular Carcinoma Cells through the Inhibition of STAT3
Kuen-Feng Chen et al.
CLINICAL CANCER RESEARCH (2010)
Sorafenib Inhibits the Shedding of Major Histocompatibility Complex Class I-Related Chain A on Hepatocellular Carcinoma Cells by Down-Regulating a Disintegrin and Metalloproteinase 9
Keisuke Kohga et al.
HEPATOLOGY (2010)
Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma
Riccardo Lencioni et al.
SEMINARS IN LIVER DISEASE (2010)
Phase II Trial of Sorafenib in Patients With Metastatic Breast Cancer Previously Exposed to Anthracyclines or Taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336
Alvaro Moreno-Aspitia et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Design and endpoints of clinical trials in hepatocellular carcinoma
Josep M. Llovet et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway
S. Wang
ONCOGENE (2008)
MCL-1 as a buffer for proapoptotic BCL-2 family members during TRAIL-induced apoptosis - A mechanistic basis for sorafenib (bay 43-9006)-induced trail sensitization
Xue Wei Meng et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with mcl-1 and cFLIPL down-regulation
Roberto R. Rosato et al.
CANCER RESEARCH (2007)
Reduction of TRAIL-induced McI-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death
M. Stacey Ricci et al.
CANCER CELL (2007)
Targeting death-inducing receptors in cancer therapy
K. Takeda et al.
ONCOGENE (2007)
Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5
Li Liu et al.
CANCER RESEARCH (2006)
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer
Scott Wilhelm et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma
Ghassan K. Abou-Alfa et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis
SM Wilhelm et al.
CANCER RESEARCH (2004)
A mechanism of cell survival: Sequestration of Fas by the HGF receptor Met
X Wang et al.
MOLECULAR CELL (2002)
Share Paper
